LBT Innovations Limited (ASX:LBT) Managing Director & CEO Brent Barnes presents on LBT's automated plate reading device for use in laboratories, regulatory clearance in the US and the size of the market opportunity at FNN's Investor Event.
- LBT Innovations (ASX:LBT) has an FDA cleared artificial intelligence platform automating manual healthcare processes
- Commercial launch underway in Australia, Europe and the US
- 1st sale completed - St. Vincent’s Hospital, Melb
- FDA cleared - 10,000 patient clinical study
- Attractive revenue model - upfront + annual fees
- Cost and efficiency gains for Pathology labs 3 times faster than manual reading
- Addressable market 2H 2019- 2,000 labs
For more, watch Managing Director & CEO Brent Barnes present.